![](https://investorshub.advfn.com/uicon/8777.png?cb=1703671008)
Friday, May 27, 2022 1:26:53 PM
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date/Short Interest/Percent Change/
Average Daily Share Volume/Days to Cover
05/13/2022 4,489,190 16.44 874,561 5.13
04/29/2022 3,855,387 4.25 963,159 4.00
04/14/2022 3,698,369 3.82 784,592 4.71
03/31/2022 3,562,356 (20.18) 1,276,819 2.79
03/15/2022 4,463,076 2.49 780,466 5.72
02/28/2022 4,354,553 5.05 1,141,138 3.82
02/15/2022 4,145,163 (4.26) 1,128,714 3.67
01/31/2022 4,329,470 18.97 1,517,532 2.85
01/14/2022 3,639,034 (0.65) 1,122,353 3.24
12/31/2021 3,662,710 (11.90) 752,924 4.86
12/15/2021 4,157,631 (15.83) 1,013,911 4.10
11/30/2021 4,939,519 3.29 626,906 7.88
11/15/2021 4,782,042 (3.95) 682,478 7.01
10/29/2021 4,978,819 4.72 563,617 8.83
10/15/2021 4,754,337 (6.31) 463,906 10.25
09/30/2021 5,074,576 (13.43) 622,927 8.15
09/15/2021 5,861,734 (7.98) 702,044 8.35
08/31/2021 6,369,946 (13.65) 700,582 9.09
08/13/2021 7,377,030 (9.09) 577,268 12.78
07/30/2021 8,114,425 2.81 583,170 13.91
07/15/2021 7,892,883 (3.03) 678,849 11.63
06/30/2021 8,139,602 (17.77) 1,344,492 6.05
06/15/2021 9,898,014 (2.47) 995,026 9.95
05/28/2021 10,148,533 (5.75) 982,073 10.33
05/14/2021 10,768,141 1.68 830,745 12.96
04/30/2021 10,590,475 (4.60) 774,264 13.68
04/15/2021 11,101,318 10.45 743,411 14.93
Recent VKTX News
- Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 • PR Newswire (US) • 07/17/2024 08:05:00 PM
- Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association • PR Newswire (US) • 06/24/2024 11:33:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:10:11 AM
- Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) • PR Newswire (US) • 06/04/2024 11:05:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2024 08:03:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 05/22/2024 09:12:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/22/2024 08:33:26 PM
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/24/2024 08:05:00 PM
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
- Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 • PR Newswire (US) • 04/17/2024 08:05:00 PM
- Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 • PR Newswire (US) • 03/26/2024 11:03:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:54:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 12:52:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:52:52 PM
- Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares • PR Newswire (US) • 03/04/2024 09:45:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/01/2024 09:13:40 PM
- Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock • PR Newswire (US) • 02/29/2024 01:50:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 10:21:23 PM
- Viking Therapeutics Announces Proposed Public Offering of Common Stock • PR Newswire (US) • 02/27/2024 09:19:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:04:52 PM
- Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity • PR Newswire (US) • 02/27/2024 12:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/10/2024 01:59:57 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:01:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:40:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 12:38:45 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM